Diagnostic assay for Wiskott-Aldrich syndrome and genetically related disorders
The methods and compositions of the invention find use in the clinical diagnosis of primary immunodeficiencies, particularly Wiskott-Aldrich related syndromes. The compositions of the invention include isolated nucleic acid molecules and oligonucleotide pairs suitable for use in amplifying regions of the Wiskott-Aldrich syndrome protein gene and in determining the nucleotide sequence of the Wiskott-Aldrich syndrome protein gene in a patient. The invention facilitates efficient, cost-effective amplification of one or more regions of the Wiskott-Aldrich syndrome protein gene. The nucleotide sequence of amplified DNA comprising one or more regions of the Wiskott-Aldrich Syndrome Protein gene can be determined using the methods and compositions of the invention. Knowledge of the patient's nucleotide sequence in the Wiskott-Aldrich Syndrome Protein gene allows diagnosis of the patient's primary immunodeficiency.
1. An isolated nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence set forth in SEQ ID NO:7 or SEQ ID NO:8.
2. An oligonucleotide pair comprising a first nucleic acid molecule and a second nucleic acid molecule, wherein said first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID No: 7 and wherein said second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID No: 8.
3. A kit for performing a method of amplifying a region of the Wiskott-Aldrich syndrome protein gene comprising an oligonucleotide pair consisting of:
a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 7 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 8.
4. The kit of claim 3 , further comprising 2, 3, 4, 5 or 6 oligonucleotide pairs selected from the group of oligonucleotide pairs consisting of:
(a) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 1 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 2;
(b) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 3 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 4;
(c) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 5 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 6;
(d) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 9 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 10;
(e) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 11 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 12;
(f) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 21 and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 22;
(g) a first nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 11, or SEQ ID NO: 21; and a second nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 12, or SEQ ID NO: 22.
5. The oligonucleotide pair of claim 2 , wherein said first and second nucleic acid molecules allow amplification of a region of the Wiskott-Aldrich syndrome protein gene.